The start of a new wave: Developments in proteasome inhibition in multiple myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901YVN" target="_blank" >RIV/61988987:17110/18:A1901YVN - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/18:E0107191

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ejh.13071" target="_blank" >http://dx.doi.org/10.1111/ejh.13071</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ejh.13071" target="_blank" >10.1111/ejh.13071</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The start of a new wave: Developments in proteasome inhibition in multiple myeloma

Popis výsledku v původním jazyce

Multiple myeloma (MM) accounts for 10% of hematological cancers. Stem cell transplantation remains the cornerstone of first-line treatment for eligible patients, but historically, pharmaceutical treatment options for MM have been limited. The proteasome was identified as a target for MM therapy in the early 2000s and, in 2004, the boronic acid proteasome inhibitor bortezomib gained European approval. Bortezomib now plays a major role in MM treatment, but the duration of its use can be limited by toxicities such as peripheral neuropathy and the development of resistance. A new generation of proteasome inhibitors has since entered the treatment landscape: carfilzomib, an epoxyketone-based agent with a distinct mode of action, high clinical efficacy, and lower levels of peripheral neuropathy compared with bortezomib, received approval in 2015 for use in patients with relapsed and/or refractory MM (RRMM). Ixazomib, a second-generation, orally administered, boronic acid proteasome inhibitor, has also been approved for use in patients with RRMM. In just over a decade, proteasome inhibitor-based regimens have become an integral component of MM treatment; with more proteasome inhibitors in development, this remains a vibrant research area with potential to improve the lives of patients with MM in the years to come.

Název v anglickém jazyce

The start of a new wave: Developments in proteasome inhibition in multiple myeloma

Popis výsledku anglicky

Multiple myeloma (MM) accounts for 10% of hematological cancers. Stem cell transplantation remains the cornerstone of first-line treatment for eligible patients, but historically, pharmaceutical treatment options for MM have been limited. The proteasome was identified as a target for MM therapy in the early 2000s and, in 2004, the boronic acid proteasome inhibitor bortezomib gained European approval. Bortezomib now plays a major role in MM treatment, but the duration of its use can be limited by toxicities such as peripheral neuropathy and the development of resistance. A new generation of proteasome inhibitors has since entered the treatment landscape: carfilzomib, an epoxyketone-based agent with a distinct mode of action, high clinical efficacy, and lower levels of peripheral neuropathy compared with bortezomib, received approval in 2015 for use in patients with relapsed and/or refractory MM (RRMM). Ixazomib, a second-generation, orally administered, boronic acid proteasome inhibitor, has also been approved for use in patients with RRMM. In just over a decade, proteasome inhibitor-based regimens have become an integral component of MM treatment; with more proteasome inhibitors in development, this remains a vibrant research area with potential to improve the lives of patients with MM in the years to come.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EUROPEAN JOURNAL OF HAEMATOLOGY

ISSN

0902-4441

e-ISSN

1600-0609

Svazek periodika

2

Číslo periodika v rámci svazku

101

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

17

Strana od-do

220-236

Kód UT WoS článku

000439773500013

EID výsledku v databázi Scopus

2-s2.0-85046335606